OptimizeRx’s (OPRX) Buy Rating Reaffirmed at Roth Mkm

Roth Mkm restated their buy rating on shares of OptimizeRx (NASDAQ:OPRX) in a research note issued to investors on Thursday morning,Benzinga reports. Roth Mkm currently has a $16.00 target price on the stock, down from their previous target price of $20.00.

Other equities analysts have also recently issued reports about the stock. Stifel Nicolaus cut their target price on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday. Barclays reduced their target price on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday. JMP Securities decreased their price target on OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a research note on Thursday. Royal Bank of Canada reduced their price objective on OptimizeRx from $17.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday, August 16th. Finally, B. Riley initiated coverage on OptimizeRx in a report on Thursday, July 25th. They set a “buy” rating and a $18.50 price objective on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.42.

OptimizeRx Stock Performance

Shares of OPRX stock traded down $0.21 during trading hours on Thursday, hitting $3.85. The company’s stock had a trading volume of 483,298 shares, compared to its average volume of 142,043. The company has a 50 day moving average of $6.67 and a 200 day moving average of $9.03. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $16.65. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.27.

Institutional Investors Weigh In On OptimizeRx

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets boosted its position in OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after acquiring an additional 2,414 shares in the last quarter. Quest Partners LLC increased its holdings in OptimizeRx by 15,965.6% in the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after buying an additional 9,739 shares during the last quarter. Greenwood Capital Associates LLC boosted its stake in shares of OptimizeRx by 8.0% during the third quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock worth $520,000 after buying an additional 4,999 shares during the period. Janney Montgomery Scott LLC purchased a new position in OptimizeRx in the third quarter valued at about $810,000. Finally, Rice Hall James & Associates LLC increased its stake in shares of OptimizeRx by 24.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock worth $4,751,000 after purchasing an additional 119,306 shares in the last quarter. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.